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Abstract The aim of the present study was to examine the
effect of lipopolysaccharide (LPS)-induced inflammation on
AMP-activated protein kinase (AMPK) and pyruvate dehy-
drogenase (PDH) regulation in human skeletal muscle at rest
and during exercise. Nine young healthy physically inactive
male subjects completed two trials. In an LPS trial, the sub-
jects received a single LPS injection (0.3 ng/kg body weight)
and blood samples and vastus lateralis muscle biopsies were
obtained before and 2 h after the LPS injection and immedi-
ately after a 10-min one-legged knee extensor exercise bout
performed approximately 2½h after the LPS injection. The
exercise bout with muscle samples obtained before and im-
mediately after was repeated in a control trial without LPS
injection. The plasma tumor necrosis factor α concentration
increased 17-fold 2 h after LPS relative to before. Muscle
lactate and muscle glycogen were unchanged from before to
2 h after LPS and exercise increased muscle lactate and
decreased muscle glycogen in the control (P<0.05) and the
LPS (0.05≤P<0.1) trial with no differences between the trials.
AMPK, acetyl-CoA carboxylase (ACC) and PDH phosphor-
ylation as well as PDHa activity were unaffected 2 h after LPS
relative to before. Exercise decreased (P<0.05) PDH and
increased (P<0.05) AMPK and ACC phosphorylation as well
as increased (P<0.05) PDHa activity similarly in the LPS and
control trial. In conclusion, LPS-induced inflammation does
not affect resting or exercise-induced AMPK and PDH regu-
lation in human skeletal muscle. This suggests that metabolic
flexibility during exercise is maintained during short-term
low-grade inflammation in humans.
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Introduction
Skeletal muscle has an extraordinary ability to regulate substrate
choice and utilization according to availability [11, 32]. The
exercise-induced enhancement of glucose and fat oxidation in
skeletal muscle ensuresATP production formuscle contractions,
and the interaction between fatty acids and glucose regulates the
relative fatty acid and glucose oxidation and contributes to
efficient substrate utilization [32]. Regulation of substrate choice
and substrate utilization may however be influenced by meta-
bolic changes and contribute to metabolic dysfunction. For
example, chronically elevated plasma free fatty acid (FFA)
levels will inhibit glucose oxidation and elevated plasma glu-
cosemay inhibit fat oxidation in skeletal muscle [19, 23, 27, 32].
Similarly, metabolically related diseases are often associated
with low-grade inflammation characterized by chronically ele-
vated levels of circulating cytokines [25] like the pro-
inflammatory cytokine tumor necrosis factor (TNF)α. Previous
studies have linked TNFα to insulin resistance in rat and human
skeletal muscle [17, 30], as well as indicated TNFα-mediated
effects on substrate utilization [35, 40, 47].
The pyruvate dehydrogenase (PDH) complex has a key
position in the regulation of substrate choice as it catalyzes the
decarboxylation of pyruvate to acetyl CoA, which represents
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the entry of carbohydrate-derived substrate into the mitochon-
dria for oxidation [33]. In accordance, exercise has been
shown to induce a rapid increase in the activity of PDH in
the active form (PDHa) in human skeletal muscle [18] con-
comitant with increased glucose oxidation [31]. Furthermore,
elevated plasma FFA has been shown to be associated with
a reduced exercise-induced increase in PDHa activity in
human skeletal muscle [20] supporting that PDH contrib-
utes to regulating substrate utilization during exercise as
part of the interaction between fatty acids and carbohy-
drates [32, 33]. The PDHa activity is thought mainly to
be regulated by phosphorylation of the PDH-E1α subunit
[22, 28] determined by the activity of PDH kinases (PDK),
which phosphorylate and inactivate the enzyme and PDH
phosphatases (PDP), which dephosphorylate and activate
PDH. Previous studies have shown that the PDK4 protein
content is up-regulated in rat and/or human skeletal muscle
by fasting and high-fat diet [26, 46] and this regulation has
been suggested to contribute to the associated changes in
PDHa activity [16]. Although the PDK4 protein content
has been shown to be unaffected during even prolonged
exercise, the PDK4 protein content has been demonstrated
to be rapidly regulated in human skeletal muscle by carbo-
hydrate availability [20] indicating a potential role of acute
changes in PDK4 protein content in PDH regulation.
Several previous studies suggest that inflammation influ-
ences PDH regulation. Repeated Escherichia coli injections
in rats have been shown to reduce the concentration of
active PDH complex and increase PDK activity [39, 40].
Moreover, the observations that treatment with TNFα re-
duced PDH activity in rat cardiomyocytes [47] and human
immune cells [36] as well as the finding that treatment with
TNFα binding protein alleviated the effects of inflamma-
tion on PDH activity [40] indicate that TNFα influences
PDH regulation. These findings are further supported by a
study showing that lipopolysaccharide (LPS) infusion for
24 h decreased PDHa activity and increased PDK4 protein
content in rat skeletal muscle [13]. On the other hand, local
infusion of LPS or TNFα in one leg did not change resting
PDH-E1α phosphorylation in human skeletal muscle [6, 9],
which may suggest that the impact of inflammation on
PDH regulation at rest depends on species, dose, or dura-
tion of the treatment.
The intracellular energy sensor, AMP-activated protein
kinase (AMPK), is also a key factor in the regulation of
substrate utilization. AMPK activity is increased both by
AMP-mediated allosteric regulation and by phosphorylation
[44] leading to stimulation of several downstream processes
aiming at increasing ATP production. In accordance, exer-
cise increases AMPK phosphorylation and activity in skel-
etal muscle leading to an enhancement of fat oxidation in
skeletal muscle through AMPK-mediated phosphorylation
and inactivation of acetyl-CoA carboxylase (ACC) [43]. As
ACC catalyzes the production of malonyl CoA, an inacti-
vation of ACC leads to reduced production of malonyl-
CoA with concomitantly less inhibition of carnitine
palmitoyltransferase I and an increased fatty acid oxidation
[15]. AMPK has been suggested to have anti-inflammatory
effects [14], and AMPK phosphorylation has been reported
to increase in human skeletal muscle after an LPS injection,
although a concomitant increase in ACC phosphorylation
was not observed [3]. This may suggest that inflammation
modifies AMPK-mediated intracellular signaling in resting
skeletal muscle.
Although previous studies indicate that inflammation af-
fects PDH and AMPK regulation, it is yet unresolved how
inflammation influences exercise-induced AMPK and PDH
regulation in human skeletal muscle. Therefore, the aim of the
present study was to test the hypothesis that LPS-induced
short-term inflammation impairs AMPK and PDH regulation




Nine physically inactive young healthy male subjects in the
range from 20 to 26 years of age with an average body mass
index of 25.6±3.7 (mean±SD) participated in the study. The
subjects were physically active less than 1 h per week. Each
subject underwent a health examination by a medical doctor.
The subjects could participate in the study if the VO2max was
less than 45 ml min−1 kg−1 and was approved by the medical
doctor. This fitness level was chosen to obtain healthy but
untrained subjects to avoid any potential effects of training
status on the effect of short-term inflammation on AMPK and
PDH regulation. A group of endurance trained subjects also
completed the experimental trials, but for another purpose
than the present study and are therefore not include in the
present study. The subjects were given both written and oral
information about the study and the subjects gave their written
consent to participate in the study. The study was performed
according to the Declaration of Helsinki and approved by the
Copenhagen and Frederiksberg Ethical committee in Den-
mark (H-1-2012-108).
Pre-testing
The VO2max was measured for each subject using an incre-
mental ergometer bicycle test (Monarch Ergomedic 839E) for
use as inclusion criteria. In addition, Wattmax was determined
during an incremental one-legged knee extensor exercise test
on a modified ergometer bicycle as previously described [29].
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The Wattmax was used to determine the resistance during the
experimental trials.
Experimental protocol
The subjects completed a LPS trial and a control trial separated
by a least 7 days. For both trials, the subjects were instructed to
eat a carbohydrate richmeal 1 h before arriving to the laboratory.
LPS trial After arriving to the laboratory, a catheter was placed
in the femoral artery and in the femoral vein of one leg and a
venflon (BD, East Rutherford, NJ, USA) was placed in an
antecubital vein in the forearm. Blood samples were obtained
from the femoral catheters and a muscle biopsy was obtained
from the vastus lateralis muscle using the needle biopsy meth-
od [8] with suction. Insertions for biopsies were made under
local anesthesia (Lidocaine, AstraZeneca, Södertälje, Sweden).
A LPS solution (100 ng/ml) was either freshly prepared from a
LPS stock (The Clinical Center, Critical Care Medicine De-
partment, Bethesda,MD, USA) or used within a week from the
preparation with storage at −20 °C. An intravenous injection of
0.3 ng/kg LPS was given through an arm venflon approxi-
mately 2.5 h after the subjects had eaten breakfast. Additional
blood samples were obtained 30, 60, 90, and 120 min after
LPS injection and additional muscle biopsies at 1 and 2 h after
LPS was given. The 1-h biopsy, all venous blood samples and
arterial blood samples obtained at 30, 60 and 90 min after the
LPS injection are not used in the present study except the
venous sample before LPS for comparison of the arterial and
venous TNFα level. After the 2-h blood and tissue sampling,
the subjects were transferred to a chair connected to a one-
legged knee extensor ergometer bicycle with the back of the
chair lying down. The right foot of the subject was tied to a rod
connected to the crank set of the modified ergometer bicycle.
The subjects first performed 1-min passive knee extensions to
warm up the leg followed by 5-min exercise at 50% ofWattmax
and 5-min exercise at 60 % of Wattmax. Additional blood
samples were obtained 8 min into the exercise and an addi-
tional muscle biopsy was obtained from the vastus lateralis
muscle of the working leg immediately as the exercise was
terminated after 10 min of exercise.
Individual insertions were made for each biopsy. Visual fat,
connective tissue, and blood were removed from the biopsies,
whichwere quickly frozen in liquid nitrogen. Themuscle biopsy
piece used for PDHa activity was frozen in liquid nitrogen
within ~15 s. The muscle biopsies were stored at −80 °C. The
blood was collected in EDTA containing tubes, which were
centrifuged and plasma was collected and stored at −80 °C.
Ear temperature, mean arterial blood pressure (MAP), and
heart rate were recorded every 15 min until 3 h after the LPS
injection. MAP monitoring continued until at least 4 h after
the LPS injection to insure that normal blood pressure regu-
lation was re-established.
Control trial After arriving to the laboratory, a venflon was
inserted in a vein in the forearm and a blood sample was obtained
through the venflon (BD). In addition, a muscle biopsy was
obtained from the vastus lateralis muscle as described above.
The subjects were placed in the chair connected to the one-
legged knee extensor ergometer bicycle with the back of the
chair lying down. The right leg of the subject was tied to the
modified ergometer bicycle and 1min of passive knee extensions
was performed followed by 5-min exercise at 50 %Wattmax and
5-min exercise at 60 %Wattmax as in the LPS trial. An additional
blood samplewas drawn after 8min of exercise and an additional
vastus lateralis muscle biopsy was obtained from the working leg
immediately after 10 min of exercise. Blood andmuscle biopsies
were handled as described for the LPS trial above.
Plasma analyses
Plasma glucose and insulin The blood was analyzed imme-
diately for blood glucose (ABL, Radiometer 725 series Acid–
base Analyzer, Denmark) and insulin was measured at The
Department of Clinical Biochemistry at Rigshospitalet, Co-
penhagen, Denmark.
Plasma TNFα The plasma TNFα was determined using a
MSD multi-spot 96 wells plate with pre-coated antibodies
(MesoScaleDiscovery, Gaithersburg, ML, USA). The plates
were measured on MSD Sector Image 2400 plate reader. The
data were analyzed using the Discovery Workbench 3.0
(MSD). The results were converted to a concentration by use
of a standard curve constructed from a serial dilution of
recombinant TNFα run alongside on each plate.
Muscle analyses
Dividing of muscle tissue A piece of wet weight muscle tissue
was chipped off and used for the PDHa activity analysis. An
additional part of the muscle biopsies was freeze-dried for at
least 48 h and these samples were dissected free from visual
blood and connective tissue under the microscope. The freeze-
dried muscle tissue was weighted out for the different analyses
and stored at −80 °C.
Muscle glycogen The muscle glycogen concentration was
determined on freeze-dried muscle tissue as glycosyl units
after acid hydrolysis as previously described [24].
Muscle lactate PCA extract was made on freeze-dried muscle
tissue as previously described [7]. Muscle lactate was mea-
sured using the auto-fluorescence ability of NADH as previ-
ously described [7].
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SDS-PAGE and Western blotting The freeze-dried muscle was
homogenized using a Tissue LyserII (Qiagen, Hilden,
Germany) and the homogenized muscle samples were made
into lysates as previously described [38]. The protein concen-
tration was determined with the bicinchoninic acid method
(Pierce, ThermoScientific, Rockford, IL, USA) using BSA as
a standard.
The lysate samples were loaded on hand casted gels (7.5–
10 %). After the gel electrophoresis, the proteins were blotted
from the gel to a PVDFmembrane (Millipore, Bedford, USA),
blocked in 3 % fish gelatin solution and incubated with
antibodies. The protein content and phosphorylation level
were determined using antibodies towards AMPK Thr172
phosphorylation (2535; Cell Signaling Technology, Berverly,
MA, USA), ACC Ser221 phosphorylation (07–303; Millipore,
Bedford, USA), PDH Ser293 (site1), PDH Ser300 (site 2), PDH
Ser295 (site 4) phosphorylation, PDH-E1α protein, AMPKα2
protein, and PDK4 protein (provided by Graham Hardie,
Dundee University, Dundee, UK). ACC protein content was
detected using streptavidin–HRP (Dako, Glostrup, Denmark).
The bands on the membranes were visualized with ECL
reagent (Millipore, Billerica, MA, USA) in a digital image
system (GE healthcare, München, DE).
PDHa activity The PDHa activity was determined as previ-
ously described [10, 12, 31]). In brief, muscle homogenate
was prepared on ice from wet weight muscle tissue using a
glass homogenizer (Kontes, Vineland, NJ, USA). Pyruvate
was converted to acetyl CoA followed by determination of
the acetyl CoA content by use of a radioactive assay. The
PDHa activity was determined as the rate of conversion of
pyruvate to acetyl CoA and normalized to the total creatine
content in each sample as previously described [34].
Statistics
Values presented are means±SE. A paired t test was used to test
the effect of LPS at rest. A two-way ANOVA with repeated
measures was used to evaluate the effect of LPS and exercise.
The data were log transformed if normality or equal variance
test failed. If a significant main effect was detected, the student
Newman–Keuls test was used to locate differences. Differences
are considered significant at P<0.05 and a tendency is reported
for 0.05≤P<0.1. Statistical calculations were performed using
SigmaPlot 11.0 (Systat Software, Inc, San Jose, CA, USA).
Results
Physical parameters
The mean arterial pressure was stable around 85–90 mmHg
and the ear temperature was unchanged around 37.0–37.6 °C.
The heart rate increased (P<0.05) from 63±3 before LPS to
83±4 beats/min 3 h after the LPS injection (Table 1).
Plasma parameters
Plasma glucose and insulin
The arterial plasma glucose concentration decreased (P<0.05)
2 h after LPS relative to before the LPS injection. Exercise did
not change the plasma glucose concentration in the LPS trial
(Table 1).
The arterial plasma insulin concentration decreased
(P<0.05) 2 h after LPS injection relative to before LPS.
Exercise did not affect the plasma insulin level in the LPS
trial (Table 1).
Plasma TNFα
Plasma TNFα was determined as a measure of the LPS-
induced inflammation. The plasma TNFα concentration be-
fore LPS injection was similar in the femoral artery and
femoral vein suggesting that arterial and venous levels can
be compared at least in a non-inflammatory state. The arterial
plasma TNFα concentration increased (P<0.05) ~17-fold 2 h
after LPS injection relative to before LPS. Exercise did not
change the plasma TNFα concentration in either trial. The
arterial plasma TNFα concentration was 13–15-fold higher
(P<0.05) in the LPS trial than the venous plasma TNFα in the
control trial before and at the end of exercise (Table 2).
Muscle analyses
Muscle glycogen
The muscle glycogen concentration was unaffected from be-
fore LPS injection to 2 h after LPS. Exercise reduced
(P<0.05) muscle glycogen 27% in the control trial and tended
to reduce (0.05<P<0.1) muscle glycogen 6% in the LPS trial.
Table 1 Physiological and plasma parameters in the LPS trial
Pre 2 h LPS/pre exercise 3 h LPS
Temperature (°C) 37.4±0.2 37.3±0.1 37.6±0.2
MAP (mmHg) 87.8±2.9 88.0±3.4 87.9±3.6







Ear temperature (°C), mean arterial pressure (MAP; mmHg), and heart
rate (beats/min) before (pre-LPS) and 2 h (2 h LPS) and 3 h (3 h LPS)
after a single LPS injection as well as arterial glucose (mmol/l) and
arterial insulin (pmol/l) at pre-LPS, 2 h LPS corresponding to before
exercise (pre-exercise) and at 8 min of exercise (exercise). The values are
mean ± SE
*P<0.05 (significantly different from pre-LPS)
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There was no significant difference in the muscle glycogen
concentration between the two trials neither before nor after
exercise (Table 3).
Muscle lactate
Muscle lactate did not change from before the LPS injection to
2 h after LPS. Exercise increased (P<0.05) muscle lactate 6.8-
fold in the control trial and tended to increase (0.05≤P<0.1)
muscle lactate 4.9-fold in the LPS trial with no difference
between the two trials neither before exercise nor after exer-
cise (Table 3).
AMPK and ACC phosphorylation
There was no difference in AMPK Thr172 and ACC Ser221
phosphorylation in skeletal muscle before and 2 h after LPS
injection (Fig. 1a, c).
The exercise bout increased (P<0.05) skeletal muscle
AMPK phosphorylation ~3-fold and ACC phosphorylation
6–7-fold in the control and LPS trial with no difference in the
responses between the trials. The AMPK and ACC
phosphorylation levels were similar in the two trials both
before and after exercise (Fig. 1b, d).
PDK4 protein
The PDK4 protein content in skeletal muscle was unchanged
by LPS injection (pre-LPS, 0.98±0.15; 2 h LPS, 1.11±0.06)
(Data not shown).
Exercise did not affect the PDK4 protein content in skeletal
muscle and there was no difference between the control and
LPS trial (control, pre-exercise, 1.29±0.13; control, post-
exercise, 1.12±0.14; LPS, pre-exercise, 1.11±0.06; LPS,
post-exercise, 1.14±0.11).
PDH-E1α phosphorylation
PDH-E1α phosphorylation at Ser293, Ser300, and Ser295
was unchanged 2 h after LPS injection relative to before
(Fig. 2a, c, e).
Exercise decreased (P<0.05) the PDH-E1α phosphoryla-
tion at site Ser293 40–50 %, site300 60–70 %, and site Ser295
30–40 % in the control and LPS trial with no difference in the
responses between the trials. The PDH-E1α phosphorylation
level was for each of the three sites similar in the control and
LPS trial both before and after exercise (Fig. 2b, d, f).
PDHa activity
The PDHa activity was unchanged 2 h after LPS injection
relative to before LPS. Exercise increased (P<0.05) the PDHa
activity ~1.8-fold in the control trial and ~2.2-fold in the LPS
trial with no difference in the response between the trials. The
PDHa activity was similar in the two trials both before and
after exercise (Fig. 3).
Discussion
The main findings of the present study are that LPS-induced
inflammation with elevated plasma TNFα concentration does
not affect the exercise-induced AMPK and PDH regulation in
human skeletal muscle. In addition, short-term inflammation
does not affect AMPK and PDH regulation at rest.
The present human study used a single LPS injection to
induce a controlled inflammation in young volunteers as a
model for low-grade inflammation as frequently used [4, 5,
36, 37]. The present observation that the LPS injection in-
creased the plasma TNFα concentration 17-fold to ~15 ng/l
2 h after the LPS injection is in accordance with several
previous studies [4, 5, 37] and shows that the anticipated
inflammatory state was obtained.
The observation that skeletal muscle PDHa activity and
PDH phosphorylation did not change 2 h after LPS injection
Table 2 Plasma TNFα concentrations
Pre-LPS 2 h LPS/pre-exercise Exercise
TNFα (ng/l) Control – 0.97±0.1 1.0±0.1
LPS 0.90±0.1 15.5±1.6*# 13.6±1.3*#
Arterial (LPS trial) and venous (control trial) plasma tumor necrosis factor
(TNF)α (ng/l) concentration before a single LPS injection (pre-LPS) and
2 h after the LPS injection corresponding to before exercise (2 h LPS/pre-
exercise) and 8 min into an one-legged knee extensor exercise bout
(exercise). The values are mean±SE
*P<0.05 (significantly different from pre-LPS); #P<0.05 (significantly
different from control at the given time point)
Table 3 Muscle glycogen and lactate concentrations





Control – 365±38 267±44*
LPS 329±32 391±49 367±35*
Lactate
(mmol kg−1 dw)
Control – 9.7±1.9 66.4±15.6*
LPS 10.9±1.3 10.8±1.4 53.2±13.3**
Glycogen (mmol kg−1 dry weight) and lactate (mmol kg−1 dry weight)
concentration in the vastus lateralis muscle before a single injection of
LPS (pre-LPS), 2 h after the LPS injection corresponding to before
exercise (2 h LPS/pre-exercise), and immediately after 10 min of one-
legged knee extensor exercise (post-exercise). The values are mean ± SE
*P<0.05 (significantly different from pre-LPS); **0.05≤P<0.1 (tends to
be significantly different from pre-LPS)
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in the current study is different from previous observations in
rats [13, 39, 40]. Hence 24 h of LPS infusion in rats has been
shown to reduce the PDHa activity in skeletal muscle [13] and
sepsis induced by repeated treatments with E. coli was asso-
ciated with reduced concentration of active PDH in skeletal
muscle [41]. The additional finding that treatment with TNFα
binding protein prevented the E. coli-induced reduction in
PDH activity suggested that TNFα is important in the LPS-
induced effects on PDH during sepsis in rats [40]. Although
the different observations may be due to species or model
differences, it seems possible that the dose and the duration of
treatment could be important. While a single injection of
0.3 ng kg−1 was used in the present study, effects on PDH
were observed in rats with 24 h of LPS infusion resulting in an
8.9-fold increase in plasma TNFα [2, 13]. In addition, while
the present study did not observe any change in muscle lactate
2 h after the LPS injection, a previous rat study using a high
dose of LPS infusion (150 μg kg−1 h−1) reported that muscle
lactate increased after 2 h of LPS treatment [2] indicating that
the inflammation inhibited the PDH. Taken together, this may
suggest that potential effects of LPS-induced inflammation on
PDH regulation evolve later than 2 h after injection. But future
experiments are needed to confirm this in humans.
Previous studies have also indicated a link between TNFα
and AMPK, although different effects have been reported.
The unchanged AMPK phosphorylation 2 h after the LPS
injection in the present human study is hence not in accor-
dance with a previous study showing that treatment of muscle
cells with TNFα decreased the AMPK activity [35]. The
current finding is in line with previous observations in


















































































































































Pre     Post     Pre    Post
LPS          Control
LPS 
Pre          2h
LPS 
Pre          2h Pre     Post      Pre Post
























Fig. 1 AMPK Thr172
phosphorylation normalized to
AMPKα2 protein content a
before (pre-LPS) and 2 h after
LPS (2 h LPS) and b before (Pre-
Exercise) and immediately after
10 min of one-legged knee
extensor exercise (Post-Exercise).
ACC Ser221 phosphorylation
normalized to ACC2 protein
content c pre-LPS and 2 h LPS as
well as d Pre-Exercise and Post-
Exercise. The results are present-
ed as arbitrary units (AU). Values
are mean ± SE. *P<0.05, signifi-
cantly different from pre-exercise
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humans, although AMPK phosphorylation increased in hu-
man skeletal muscle 4 h after a single LPS injection [3]. This
may suggest that the different observations are due to model
differences and the present findings do not oppose the possi-
bility that LPS-induced inflammation in humans increases
AMPK phosphorylation in skeletal muscle.
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Fig. 2 PDH Ser293
phosphorylation normalized to
PDH-E1α protein content a
before (pre-LPS) and 2 h after
LPS (2 h LPS) and b before (Pre-
Exercise) and immediately after
10 min of one-legged knee ex-
tensor exercise (Post-Exercise).
PDH Ser300 phosphorylation
normalized to PDH-E1α protein
content c pre-LPS and 2 h LPS as
well as d Pre-Exercise and Post-
Exercise. PDH site Ser295 phos-
phorylation normalized to PDH-
E1α protein content e pre-LPS
and 2 h LPS as well as f Pre-
Exercise and Post-Exercise. The
results are presented as arbitrary
units (AU). Values are mean ± SE.
*P<0.05, significantly different
from Pre-Exercise
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The present study is (to our knowledge) the first to examine
the impact of LPS-induced inflammation on exercise-induced
metabolic regulation in humans. The exercise-induced decrease
in PDH phosphorylation and increase in AMPK and ACC
phosphorylation as well as in PDHa activity in the control trial
are as expected based on many similar previous studies [20, 21,
28, 45]. The present finding that the exercise-induced regula-
tion of PDH, AMPK and ACC phosphorylation as well as
PDHa activity was similar in the LPS trial, where TNFα was
elevated, as in the control trial is however not as hypothesized.
As PDH activation increases carbohydrate oxidation [31, 42]
and AMPK-mediated ACC inactivation increases fat oxidation
[15, 43], these observations suggest that human skeletal muscle
maintains the ability to increase carbohydrate and fat oxidation
in response to exercise despite the presence of short-term
systemic inflammation. This conclusion is supported by the
similar increase in the muscle lactate concentration in the two
trials in the present study. In addition, it may be noted that while
exercise induced a significant decrease in muscle glycogen and
increase in muscle lactate in the control trials, these changes
only tended to be significant in the LPS trial. This is opposite of
expected based on previous animal LPS models indicating that
inflammation results in elevated lactate production [2, 13].
However, the lower statistical strength of the muscle glycogen
and lactate changes in the LPS trial does not change the
conclusion that short-term inflammation does not affect
exercise-induced PDH andAMPK regulation in human skeletal
muscle, but may suggest that inflammation affects the utiliza-
tion of muscle glycogen. But this remains to be elucidated.
The lack of effect of inflammation on exercise-induced
PDH and AMPK regulation suggests that exercise-induced
metabolic flexibility is maintained during short-term inflam-
mation, which is in contrast to previous studies showing that
elevated systemic TNFα levels [30] and a single LPS injection
[1] induce whole-body insulin resistance in humans. These
findings may suggest that insulin signaling and exercise-
induced metabolic regulation are affected differently by in-
flammation. However, it is important to note that the lack of
effect on the exercise-induced responses was observed 2½h
after LPS injection, while the LPS-induced lowering of insulin
sensitivity was demonstrated 420 min after LPS was injected.
On the other hand, the previously reported TNFα-induced
insulin resistance was observed within 2 h of TNFα infusion
with similar plasma levels of TNFα [30] as in the present
study, while the previous LPS study resulted in more than 50-
fold higher plasma TNFα concentration [1] than in the present
and previous TNFα study [30]. Although the TNFα infusion
did result in a constant elevation in plasma TNFα, while the
present study induced a gradual increase in plasma TNFα,
these considerations do support a different impact of TNFα on
insulin-mediated glucose uptake than on exercise-induced
AMPK and PDH regulation in human skeletal muscle.
As the purpose of the present study was to examine the
potential effect of inflammation with elevated plasma TNFα,
the exercise bout was placed at the time point where the
plasma TNFα concentration was expected to peak. In accor-
dance, the observation that plasma TNFα was at a similar
level (15-fold elevated) and not further increased at the sam-
pling time point during exercise (approximately 2½h after
LPS injection) relative to 2 h after LPS is in line with previous
studies showing that plasma TNFα peaks at approximately 2 h
after a single LPS injection [1, 3, 5, 37]. However, it is
certainly possible that more long-term inflammation with
more sustained elevation in plasma TNFα will affect the
exercise-induced AMPK and PDH regulation in skeletal mus-
cle, but this remains to be determined.
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Fig. 3 PDHa activity (mmol min−1 kg−1) a before (pre-LPS) and 2 h after
LPS (2 h LPS) and b before (Pre-Exercise) and immediately after 10 min
of one-legged knee extensor exercise (Post-Exercise). The PDHa activity
is normalized to total creatine in the samples. Values are mean ± SE.
*P<0.05, significantly different from pre-exercise
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As previous studies examining the impact of LPS-induced
inflammation and TNFα on PDH regulation have observed
that a down-regulation of the PDHa activity was associated
with increased PDK activity [39, 40] and PDK4 protein con-
tent [13], it may be that inflammation-induced effects on PDH
regulation require changes in PDK4 expression, whichmay be
obtained with high treatment dose and/or duration. The pres-
ent observation that the lack of effect of inflammation on PDH
regulation was associated with unchanged PDK4 protein con-
tent in skeletal muscle does support the possibility that chang-
es in PDK4 protein underlie part of the effect of inflammation
on PDH.
In conclusion, a single LPS injection resulting in 17-fold
increase in plasma TNFα concentration did not change
AMPK and PDH phosphorylation and/or activity in human
skeletal muscle at rest and did not affect exercise-induced
AMPK and PDH regulation in human skeletal muscle. This
suggests that the ability of skeletal muscle to increase glucose
and fat oxidation during exercise is maintained during short-
term inflammation with elevated plasma TNFα levels. Hence,
short-term low-grade inflammation does not seem to elicit
metabolic inflexibility during exercise in humans as has been
reported for insulin-stimulated glucose uptake at rest.
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